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Background: Opioid long-term therapy can produce tolerance, opioid-induced
hyperalgesia (OIH), and it induces dysfunction in pain descending pain inhibitory
system (DPIS).
Objectives: This integrative review with meta-analysis aimed: (i) To discuss the potential
mechanisms involved in analgesic tolerance and opioid-induced hyperalgesia (OIH). (ii)
To examine how the opioid can affect the function of DPIS. (ii) To show evidence about
the tDCS as an approach to treat acute and chronic pain. (iii) To discuss the effect of
tDCS on DPIS and how it can counter-regulate the OIH. (iv) To draw perspectives for the
future about the tDCS effects as an approach to improve the dysfunction in the DPIS in
chronic non-cancer pain.
Methods: Relevant published randomized clinical trials (RCT) comparing active
(irrespective of the stimulation protocol) to sham tDCS for treating chronic non-cancer
pain were identified, and risk of bias was assessed. We searched trials in PubMed,
EMBASE and Cochrane trials databases. tDCS protocols accepted were application
in areas of the primary motor cortex (M1), dorsolateral prefrontal cortex (DLPFC), or
occipital area.
Results: Fifty-nine studies were fully reviewed, and 24 with moderate to the high-quality
methodology were included. tDCS improved chronic pain with a moderate effect size
[pooled standardized mean difference; −0.66; 95% confidence interval (CI) −0.91 to
−0.41]. On average, active protocols led to 27.26% less pain at the end of treatment
compared to sham [95% CI; 15.89–32.90%]. Protocol varied in terms of anodal or
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cathodal stimulation, areas of stimulation (M1 and DLPFC the most common), number
of sessions (from 5 to 20) and current intensity (from 1 to 2mA). The time of application
was 20min in 92% of protocols.
Conclusion: In comparison with sham stimulation, tDCS demonstrated a superior
effect in reducing chronic pain conditions. They give perspectives that the top-down
neuromodulator effects of tDCS are a promising approach to improve management
in refractory chronic not-cancer related pain and to enhance dysfunctional neuronal
circuitries involved in the DPIS and other pain dimensions and improve pain control with a
therapeutic opioid-free. However, further studies are needed to determine individualized
protocols according to a biopsychosocial perspective.
Keywords: tDCS, hyperalgesia, opioid, pain, descending pain inhibitory system
INTRODUCTION
A recent national survey estimates that 3–4% of Americans
adults have been receiving long-term opioid therapy (Dowell
et al., 2016), and it estimated that almost 2 million meet the
DSM-IV criteria for dependence or abuse (Florence et al., 2016).
Chronic pain syndromes, defined as recurrent or persistent
pain lasting 3 months, can be related to structural changes
such as a decrease in neocortex gray matter (Geha et al.,
2009). Even if research signs of progress and new targets
appear for treating acute and chronic pain, opioids still
Abbreviations: 5-HT1A, serotonin 1A receptor; AAPT, ACTTION-American
Pain Society Pain Taxonomy; ACC, cingulate cortex; AMPA, α-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid; ATP, adenosine triphosphate; BDNF, brain
derived neurotrophic factor; CCL2, monocyte chemotactic protein; CNS, central
nervous system; COMT, catechol-O-methyltransferase; CSP, cortical silent period
reduction; CSS, central sensitization syndrome; CXCL1, chemokine CXC 1;
CXCL-12, chemokine (C-X-C motif) ligand 12; CxCRs, chemokine receptors;
DLPFC, dorsolateral prefrontal cortex; DLPT, dorsolateral pontine tegmentum;
DMN, default mode network; DOR, δ-opioid receptors; DPIS, descending
pain inhibitory system; DSM-IV, Diagnostic and Statistical Manual of Mental
Disorders; FDA, Food and Drug Administration; FPT, frontal-parietal-temporal;
GABA, γ-Aminobutyric acid; Gi, Gi protein, alpha subunit; Glx, glutamate-
glutamine; GPCR, protein-coupled receptor; GRK, G protein receptor kinase; HD-
tDCS, high-definition transcranial direct current stimulation; HIO, hyperalgesia
induced by opioids (HIO); IASP, International Association for the Study of Pain;
ICI, short intracortical inhibition decrease; iG-protein, immunoglobulin; IL-10,
interleukin 10; IL-1β, interleukin 1β; IL-6, interleukin 6; IMMPACT, Initiative
on Methods, Measurement, and Pain Assessment in Clinical Trials; KCC2,
neuron specific potassium-chloride co-transporter; KOR, κ-opioid receptors;
LTD, long-term depression; LTP, long-term potentiation; MAO, monoamine
oxidase; MCC, midcingulate cortex; MLF, medial longitudinal fasciculus; MOR,
µ-opioid receptors; mPFC, medial prefrontal cortex; MRI, magnetic resonance
imaging; MRS, magnetic resonance spectroscopy; MT, motor evoked potential;
NAA, N-acetyl aspartate; NIBS, non-invasive brain stimulation; NMDAr, N-
methyl-D-aspartate receptor; NPS, numeric pain scale; NSAIDs, nonsteroidal anti-
inflammatory drugs; OIH, opioid-induced hyperalgesia; ORL-1, opioid receptor-
like 1; OUD, opioid use disorders; P2X4, purinergic ionotropic receptors 4;
P2X7, purinergic ionotropic receptors 7; PAG, periaqueductal gray matter; PCA,
patient-controlled analgesia; PFC, prefrontal cortex; PKC, protein kinase C; RN,
red nucleus; rTMS, repetitive transcranial magnetic stimulation; RVM, rostral
ventromedial medulla; SNRIs, selective norepinephrine reuptake inhibitors; SSRIs,
serotonin reuptake inhibitors; tDCS, transcranial direct current stimulation; TLR4,
Toll 4 type receptors; TMS, transcranial magnetic stimulation; TNFα, tumor
necrosis factor alpha; TrkB, tropomyosin receptor kinase B; VAS, visual analog
scale; VPL, ventral posterolateral nucleus; VPM, ventral posteromedial nucleus.
representing the gold standard analgesics. However, opioid
treatments induce several side effects, among them, are the
analgesic tolerance and opioid-induced hyperalgesia (OIH).
These phenomena are closely related to the dysfunction of the
descending pain inhibitory system (DPIS). Hence to comprehend
the relevance of new therapeutic approaches in this field, it
is essential an integrated view of their potential properties
to block processes involved in the neurobiology of tolerance
and OIH. Thereby, we conduct the reader to a brainstorm
of this question to integrate concepts related to pain, opioids
effects as neuromodulators (analgesia, tolerance, and OIH and
dysfunction of descending pain inhibitory system) and the
impact of transcranial neuromodulatory techniques. Also, we
present some essential technical aspects of how to use of tDCS,
evidence about their effect on pain and future perspectives.
An Integrative View of Chronic Pain Opioid
Use and Transcranial Neuromodulation
Chronic pain is maladaptive response related to a reduction
in the neurogenesis at the hippocampus (Lanz et al., 2011)
and a decreased volume of the ventromedial prefrontal cortex
(VMPFC) (Abdallah and Geha, 2017). Other changes found in
chronic pain were a gray matter density decrease in the cerebral
cortex, specifically in areas such as cingulate, insular, prefrontal
and dorsolateral, somatosensory, thalamus, motor cortex, and
brainstem (Kuchinad et al., 2007). These changes include
neurodegeneration related to the severity of pain (Lefaucheur
et al., 2006, 2011; May, 2008). Aligned with these neuroimage
findings, neurophysiological measures by transcranial magnetic
stimulation (TMS) indicate a dysfunction in the cortical
excitability measures and the corticospinal pathways (Niddam
and Hsieh, 2009). Such changes include increased motor evoked
potential (MT), cortical silent period reduction (CSP) and short
intracortical inhibition decrease (ICI), which suggest a disruption
of cortical inhibition mechanisms (Gussew et al., 2011; Huang
et al., 2017; Cardinal et al., 2019). According to Lefaucheur
et al. (2006), the lack of inhibitory mechanisms contributes to
increasing the cortical excitability and indicates an imbalance
in GABAergic and glutamatergic systems (Mhalla et al., 2010).
These dysfunctions in pain processing also include altered
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intrinsic brain connectivity. In chronic pelvic pain related to
endometriosis, it was found greater connectivity between the
anterior insula region with the medial prefrontal cortex (mPFC).
The connectivity level was correlated positively with the severity
of pain, anxiety, and depression (As-Sanie et al., 2016). Similar
results were found in fibromyalgia (Napadow et al., 2010, 2012),
and chronic low back pain (Loggia et al., 2013).
Likewise, in persons addicted to opioids, a decreased
functional connectivity in brain regions such as the nucleus
accumbens, anterior insula, and amygdala subdivisions has been
involved in the regulation of affect, impulse control, reward,
andmotivational functions. Besides, more prolonged exposure to
opioid prescription is correlated with a bilateral volumetric loss
in the amygdala compared to controls (Upadhyay et al., 2010).
Although some of these changes likely seem reversible after pain
treatment (e.g., gray matter volume loss; Maarrawi et al., 2013)
and after treatment with pregabalin (Kim J. et al., 2013) and
acupuncture (Napadow et al., 2012), both treatments reduced the
connectivity in these regions of the default mode network (DMN)
related to pain processing. These set of symptoms reflect changes
responsible for the shift of the sensory system physiological to
pathological pain hypersensitivity, which comprises mechanisms
of central sensitization syndrome (CSS) (Yunus, 2015).
The International Association for the Study of Pain (IASP)
defines “central sensitization” broadly as the “increased
responsiveness in the pain pathways neurons to their normal or
subthreshold afferent input.” This phenomenon is a consequence
of perturbation of the nociceptive system with the peripheral
or central sensitization, and it is involved in the hyperalgesia
(Brietzke et al., 2019). In chronic pain, the CCS is linked to the
cognitive depressed mood, fatigue, and catastrophizing thoughts
and disability due to pain (Caumo et al., 2017; Brietzke et al.,
2019). This increased excitability and reduced inhibition in
the systems of pain processing increase the gain of incoming
sensory information, resulting in exaggerated pain, secondary
hyperalgesia, allodynia, and temporal summation (Staud et al.,
2001; Price et al., 2002).
Although we have witnessed a leap forward in our
comprehension of the mechanistic underpinnings of pain,
and the potential treatment targets have grown, it is still
persistent a gap between pain research and the pain management
in the clinical setting, which remains to be a challenge.
Among drugs currently used to treat chronic pain, opioids
are frequently prescribed. In the US, ∼3–4% of the adult
population received long-term opioid therapy. However,
this prescription is not supported by evidence, because the
efficacy of opioids in randomized clinical trials lasts primarily
12 weeks or less (Dowell et al., 2016). Nonopioids drugs
currently used include selective norepinephrine or serotonin
reuptake inhibitors (SNRIs and SSRIs), membrane stabilizers
(e.g., anticonvulsants), acetaminophen, non-steroidal anti-
inflammatory drugs (NSAIDs), etc. (Nicol et al., 2017). Even
though these drugs are FDA-approved, according to the criteria
of IMMPACT consensus statement (Gewandter et al., 2015),
which defines an effect on pain reduction of considerable
magnitude of at least a 50% (alternatively 30% or moderate pain
relief), and the effect sizes for many of these treatments are small
(Nicol et al., 2017). Another aspect to consider is their side-
effects, particularly with opioids, such as sedation, nausea, and
their reduced long-term efficacy due to receptor downregulation.
According to the extensive literature in non-cancer chronic
pain, the prescription of opioid drugs should consider a proper
balance between the benefits and the risk for addiction. Such
factors associated with opiate dependence, include psychosocial
problems (e.g., childhood neglect, abuse, or trauma), mental
disorders (e.g., depression and anxiety) and to have a history
of another dependence (Busse et al., 2017). The reliance of
substance comprises tolerance, defined by either a markedly
increased amounts of the abuse substance to the desired effect
and a diminished effect with continued use and withdrawal
symptoms (Busse et al., 2017). In addition to the dependence,
the opioids can elicit an unexpected increase in pain sensitivity.
This phenomenon is known as hyperalgesia induced by opioids
(HIO). Its mechanism remains still obscure, even though
abnormal functional features have been identified, mainly by
imaging and neurophysiological measures. Although the OIH
and the tolerance may share some neurochemical mechanisms,
at the clinical setting cannot define where one ends and initiates
the other or if they are a continuum of the same phenomenon.
The OIH and dependence, both can be involved in chronic pain
refractory, and they can constitute a mechanism underpinning
the inadequate pain control, either in opioid use or in addicts
to opiate.
Thus, therapeutic approaches that alter the membrane
potential and could change the dysfunctional plasticity within
pain circuits, they may also affect the nuclei in the thalamus
and subthalamic regions (Strafella et al., 2004; Lang et al., 2005;
Moreno-duarte et al., 2014). Taking this into account is plausible
that the repetitive transcranial magnetic stimulation (rTMS) and
transcranial direct current stimulation (tDCS) may be promising
alternatives for this context. Although the FDA approved the
TMS for the treatment of major depressive disorder symptoms
treatment-resistant after use of two or three antidepressant
medicines with lack of adequate response (Nemeroff, 2007)
and the rTMS was approved for chronic neuropathic pain in
Europe (Lefaucheur et al., 2006; André-Obadia et al., 2014),
it has not been approved for chronic pain treatment yet. At
present, the device to apply TMS is relatively expensive and
need to be done under direct supervision in medical centers.
tDCS, on the other hand, is a cheaper and easier-to-use type
of stimulation technique. TMS pulse can generate currents
capable of depolarizing neurons until it reaches the threshold
for firing action potentials, whereas tDCS modulates the resting
membrane potential and require less sophisticated equipment
than TMS. The tDCS requires two electrodes, cathode, and
anode, arranged in different positions to create a direct current
flow of low intensity (1 or 2mA) that targets a specific region
of the cerebral cortex. However, it is essential to consider that
its effects, as well as the effect of the pharmacological treatment,
can be modified by genetic polymorphisms of BDNF and
monoamines [e.g., monoamine oxidase (MAO), and to catechol-
O-methyltransferase (COMT)] and several other factors such as
sex, age, central nervous disease, medicines with effect in the
central nervous system, etc. Also, tDCS effects are likely to be
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neuroplasticity state dependent, since previous study found that
serumBDNF predicts the impact of tDCS on behavioralmeasures
in chronic pain conditions (Souza et al., 2018).
This integrative review with meta-analysis has the following
aims: (i) To discuss the potential mechanisms involved in
analgesic tolerance and opioid-induced hyperalgesia (OIH). (ii)
To examine how the opioid can affect the function of descending
pain inhibitory system (DPIS). (ii) To show evidence about the
tDCS as an approach to treat chronic pain. (iii) To discuss the
effect of tDCS on DPMS and how its impact can counter-regulate
the OIH. (iv) To draw perspectives for the future about the tDCS
effects as an approach to improve the dysfunction in the DPIS in
chronic non-cancer pain.
Opioids Effects as Neuromodulators:
Analgesia, Tolerance, and OIH and
Dysfunction of Descending Pain Inhibitory
System
Analgesia Induced by Opioids
More than 200 years ago, the German Friedrich Sertürner
isolated an alkaloid Crystal from opium, extracted from poppy,
and called it morphine. After the determination of morphine
structure in 1920, the synthesis of new opioids compounds
derived from morphine and based on its chemical structure
has begun (Huxtable and Schwarz, 2001). In 1939, meperidine
emerged as the first entirely synthetic opioid. Fentanyl, another
opioid, was available since 1960. Between 1974 and 1976, were
developed some fentanyl analogs: carfentanil (1974), sufentanil
(1974), lofentanil (1975), alfentanil (1976) (Janssen, 1982) and in
the early 90’s remifentanil was available for clinical use. Opioids
bind to receptors in the central nervous system (CNS) µ (MOR),
δ (DOR), κ (KOR). Another type of receptor is ORL-1, mostly
located in the solitary tract nucleus, periaqueductal gray matter,
frontal cortex, thalamus, and central gelatinous substance of
the spinal cord (Butour et al., 1998). These opioids receptors
are opioid conjoining to inhibitory G—(iG)-protein (Waldhoer
et al., 2004), and they can be agonist-antagonists. The clinical
effects include analgesia and sedation, which are produced by
a reduction to intracellular calcium influx and to impair the
quantity of the neurotransmitters in the cleft synapsis. This
cascade of events that lead to hyperpolarization of membranes
is presented in Figure 1.
Tolerance to Opioids Analgesic Effects
Tolerance to opioid analgesia involves the desensitization of
Mu opioid receptor (MOR) (see Dang and Christie, 2012;
Williams et al., 2013). The desensitization corresponds to a
loss of effectiveness to agonist by repeated exposure (Dang
and Christie, 2012; Williams et al., 2013). The homologous
desensitization, i.e., the activation of a receptor type provokes
its desensitization (i.e., MOR activation desensitizes MOR),
and heterologous desensitization when the activation of
another receptor desensitizes MOR, such as the desensitization
described between MOR and chemokine receptors (CxCRs)
(see Parsadaniantz et al., 2015). For instance, the desensitization
of MOR by the interaction between MOR-CxCr4 and MOR-
Cx3Cr1 in the periaqueductal gray matter (PAG) (Heinisch
et al., 2011). Neurons treated in vitro with the respective
CxCr4 or Cx3Cr1 agonists displayed decreased morphine-
induced electrophysiological activity. And, intraspinal CXCL12
administration diminished morphine analgesia, while CXCR4
antagonist potentiated morphine analgesia (Rivat et al., 2014).
At a molecular view, CxCRs activate protein kinase C (PKC),
which phosphorylates the intracytoplasmic tail of MOR (see
Williams et al., 2013). MOR phosphorylation uncouplers MOR
from Gi [inhibitory protein-conjoined receptor (GPCR)]. Then,
G protein receptor kinase (GRK) and arrestin are recruited to
MOR, leading to MOR internalization and the result this cascade
is the analgesic tolerance (see Williams et al., 2013). CxCR
activation can also lead to activation of signal-regulated kinase
(ERK) in the pathway that decreases nociceptive thresholds and
hence induces hyperalgesia (see Parsadaniantz et al., 2015). The
mechanisms involved in the tolerance are presented in Figure 2.
The dependence motivating effects of abuse drugs occur
through the activation of the mesocorticolimbic dopaminergic
pathway, a central system that mediates the effects of
reinforcement (Uhl et al., 2019). The primary circuit of
this system comprises dopaminergic neurons in the ventral
tegmental area, which has connections with prefrontal cortex and
accumbens nucleons, while the emotional aspects of dependence
memories are associated with amygdala, hippocampus, and
hypothalamus. The amygdala is involved in the conditioned
response and gives the emotional value to perception after drug
use. Also, the amygdala participates in emotional memory,
providing a positive or negative value of new information,
whereas the hypothalamus receives the afferents of the nucleus
accumbens to trigger an autonomic and neuroendocrine
response (Uhl et al., 2019).
The most common strategy to face opioid dependence is
pharmacological, which comprises methadone, used to treat the
Opioid Use Disorders (OUD). The buprenorphine, naltrexone
are equally efficacious in non-injection opioid analgesia users
(Potter et al., 2013). Despite methadone being a mu opioid
receptor agonist and one an NMDAr antagonist, OIH can still
develop (Compton et al., 2012). A high number of patients
with OUDs reported persisted with chronic pain, even after
conversion to methadone (Compton et al., 2012; Dennis et al.,
2015). Although behavioral and pharmacological therapies have
been used to treat abstinence in alcohol and drug abuse, relapse
rates continue higher than 60% (HHS and Office of the Surgeon
General, 2016). This suggests a need for further research to
develop more effective treatments.
Hyperalgesia Induced by Opioids
The HIO seem to depend on complex interactions between the
various cell types that make up the central nervous system,
such as the activation of opioid receptors in neurons, astrocytes,
and microglia, associated with the release of pro-inflammatory
cytokines, events crucial for the understanding of the mechanism
of opioid-induced hyperalgesia. In neurons, activation of opioid
receptors may decrease glutamate reuptake in the synaptic
cleft, in addition to increasing NMDA receptor activity. Still in
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FIGURE 1 | Cell mechanisms of opioids action. In presynaptic neuron have inhibition of intracellular calcium influx and impairment in neurotransmitters release. In a
postsynaptic neuron, cascade events induce to hyperpolarization state. cAMP, cyclic adenosine monophosphate; RPBE, response of cAMP to the protein binding
element; Ca2+, calcium; K+, potassium; Na+, sodium; +, excitatory; –, inhibitory. 1. Inhibition of adenylate cyclase reduces the cyclic adenosine monophosphate
(cAMP); and second messengers. 2. With this, cAMP reduction allow the openness of the potassium channels and promote the postsynaptic cell hyperpolarization. 3.
The concomitant activation of presynaptic opioid receptors of C and Aδ fiber inhibits indirectly calcium influx, which decreases cAMP levels and blocks
neurotransmitters release—glutamate, substance P and calcitonin gene-related peptide (CGRP).
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FIGURE 2 | Schematic representation of neuronal mechanisms underlying opioid tolerance development. Tolerance event: Decreases membrane potential threshold,
increases the action-potential duration (APD), and increases neurotransmitter release. APD, action-potential duration; IEG, immediate early genes (c-Fos, FosB); PKA,
protein Kinase A; CREB, cAMP response element-binding protein; pCREB, phosphorylated CREB protein; Gi/o, inhibitory G protein; Gs, excitatory G protein;
CaMK-II, calcium/calmodulin dependent protein kinase II; PLA2, phospholipase A2; NO, nitric oxide; nNOS, neuronal nitric oxide synthase; HPETE,
hydroperoxyeicosatetraenoic acid; +, excitatory; –, inhibitory.
neurons, the morphine-induced astrocyte BDNF release, which
causes a decrease in Cl- transporters of type KCC2, reversing
the concentration gradient of this ion. In neuropathic and
chronic inflammatory pain conditions, GABAergic inhibitory
control is decreased, leading to increased excitation and central
sensitization (Malcangio, 2018).
According to Ferrini et al. (2013), rats treated with
morphine for seven days altered Cl- homeostasis (together
with a downregulation of the K+-Cl– co-transporter KCC2)
homeostasis in spinal lamina l neurons. Subsequently, it was
observed a reversal potential for GABAa currents, making
neurons become more depolarized. When exogenous GABA was
applied, they saw GABA that it is evoking a biphasic response,
initially with an outward flow, which was followed by a shift to
an inward current. This shift was not found in the case of saline-
treated rats. Therefore, it is plausible to conclude an excitatory
effect had taken place, which was associated with hyperalgesia.
When researchers blocked BDNF-TrkB signaling, it was observed
the preservation of Cl– homeostasis and a reduction in
hyperalgesia. In astrocytes, chronic-activated opioid receptors
may promote the release of pro-inflammatory cytokines, such
as tumor necrosis factor alpha (TNFα), interleukin-1β (IL-
1β), IL-6, IL-10, monocyte chemotactic protein 1 (CCL2) and
chemokine CXC 1 (CXCL1). Besides, morphine can inhibit
astrocyte glutamate transporters, promoting an increase in the
extracellular concentration of this neurotransmitter (Roeckel
et al., 2016).
On the other hand, opioid receptors activated in microglia
leads to a rise in the expression of purinergic ionotropic
receptors P2X4 and P2X7, as well as Toll 4 type receptors
(TLR4) (Hutchinson et al., 2011; Grace et al., 2014) further
increasing the release of pro-inflammatory cytokines, as well
as ATP and nitric oxide (Zhou et al., 2010). In turn, the
cytokines released from astrocytes and microglia will activate
their respective receptors located in nociceptive neurons, causing
desensitization of the opioid receptors, which will cause a
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decrease in the analgesic effect (Roeckel et al., 2016). The
acute and chronic morphine administration activate cytokines
released by astrocytes. Acute morphine exposure over satellite
glial cells in the dorsal root ganglia (DRG) leads to upregulation
of inflammatory cytokine interleukin 1-beta (IL-1β). Likewise,
chronic morphine administration demonstrates upregulation of
inflammatory cytokine (IL-1β) in spinal astrocyte (Berta et al.,
2012). About chronic use of morphine, microglia cells also
release proinflammatory cytokines (Merighi et al., 2013). The
opioid desensitization receptor occurs by distinct mechanisms
of desensitization potential between opioid receptors and
inflammatory substances that participate in the G-protein-
coupled systems (Szabo et al., 2002). Other neurons and
glia systems (calcium, MAP kinases pathway, and nuclear
factor-κB) also may be acting in this different desensitization
(Haddad, 2002).
Also, activation of cytokine receptors in neurons causes an
increase in the expression of excitatory NMDA-like glutamate
receptors leading to increased sensitivity to pain (Roeckel et al.,
2016). Hence, these neuronal processes contribute to activation of
neuroexcitatory mechanisms involved in long-term potentiation
(LTP) and descending pain facilitation (Chu et al., 2011; Lee
et al., 2011). Together, these cellular and molecular mechanisms
lead to the sensitization of neurons and contribute to the
development of hyperalgesia induced by morphine and its
derivatives. The OIH is pronociceptive changes that occur in
combined with catecholamine release, and other factors have
been linked with withdrawal-induced hyperalgesia, or on long-
term opioid therapy for chronic pain (Bie et al., 2003). For clinical
purposes, these two phenomena are difficult to handle, since the
development of analgesic tolerance will lead to an increase in the
opiate dosage, which in turn will induce an enhancement of OIH.
The neuronal pathways involved in OIH, such as activation of
neuronal MOR and the regulation of intracellular mechanisms
involved in OIH are presented in Figure 3.
Impact of Genetic Polymorphisms in the
Pain Modulatory System and Treatment
Effect
The susceptibility to opioid physical dependence, tolerance, and
opioid-induced hyperalgesia (OIH) display a significant degree of
heritability (>60%) (Kest et al., 2002; Wilson, 2003; Liang et al.,
2006a,b). In humans, studies with twin and families estimated
that 40–60% of opioid dependence is driven by genetic factors
(Yuferov et al., 2010). Although few causal genetic variants have
been identified (Gelernter et al., 2014), the impact of these genetic
aspects on the opioid dependence need to be determined. Serum
BDNF levels were found to be significantly higher in Val/Val
carriers than in Met/ Val or Met/Met in heroin users (Roviš
et al., 2018). Besides, some prefrontal cortical areas are involved
in the inhibition of nociception (Petrovic et al., 2002). The
descending pain inhibitory pathway is modulated by the central
catecholaminergic systems (Basbaum and Fields, 1979). The
functional polymorphismVal158Met (rs4680) of the Catechol-O-
methyltransferase (COMT) gene, which regulates themetabolism
of dopamine and noradrenaline can be related to higher pain
sensitivity. The Val158Met variant of the substitution of the
amino acid valine (Val) for methionine (Met) at codon 158 is
related to a breakdown of dopamine and noradrenaline up to
four times for the valine allele compared to methionine. Hence,
they have available lower levels of dopamine/noradrenaline in the
synaptic cleft (Lotta et al., 1995). In the same way, the Val158Met
polymorphism of COMT can influence the impact of the tDCS
on pain and depression. The polymorphisms of BDNF has been
pointed out as a factor that influences the neuromodulatory effect
of pharmacological (e.g., morphine, antidepressants, etc.) and
non-pharmacological therapies (tDCS, TMS, etc.).
The Val66Met (rs6265) polymorphism of the BDNF gene
resulted in the substitution of an amino acid valine to methionine
in the pro-BDNF peptide. Then, three genotypes are possible
Val/Val, Val/Met, or Met/Met, respectively (Mowla et al., 2001;
Hariri et al., 2003). This polymorphism has been extensively
studied and may affect the secretion of BDNF (Egan et al., 2003),
regulate cell survival, growth, and modulate synaptic changes
(Mowla et al., 2001; Hariri et al., 2003; Frielingsdorf et al., 2010).
Met carriers were associated with the reduction of volume in
the hippocampus (Pezawas et al., 2004; Reiser et al., 2007),
and dorsolateral prefrontal cortex. Val66Met polymorphism is
associated with cortical maturation in children and adolescents
with and without psychiatric disorders (de Araujo et al., 2018).
Met carriers were also associated with an increased risk for
anxiety trait (Arias et al., 2012), suicide behavior in Asian
and Caucasian population (González-Castro et al., 2017) and
alcohol dependence (Matsushita et al., 2004). On the other hand,
in Han Chinese, higher Val frequency was found in heroin
users. However, Val allele carriers had a later onset of heroin
abuse compared to Met allele carriers (Cheng et al., 2005). In
addition, researchers found a significant association between
BDNF Val66Met and worse treatment outcomes among Met
carriers (Heinzerling et al., 2012). Besides, Met carriers reported
more time- and cost-intensive heroin-seeking behavior than did
carriers of the Val/Val (Greenwald et al., 2013).
BDNF is a neurotrophin that modulates long-term
potentiation (LTP), and it has a central role in sensitization
of pain pathways at the spinal level. In the presence of
inflammation, the BDNF is upregulated in the lifetime of spinal
cord injury it promotes a process of adaptive plasticity and
functional recovery. Although the effect of BDNF is multifaceted,
at the medullary level it is associated (i) expression of TrkB
receptor and downstream kinases, (ii) modifies GABAergic
transmission by altering the appearance of chloride channels,
and (iii) activation of cells of astroglia. BDNF potentiate the
metaplastic changes at the medullary level that are essential to
spinal function, especially after spinal cord injury (Garraway
and Huie, 2016). Although the findings are still incipient and
not conclusive, BDNF levels seem to be related to anodal tDCS
over the M1 in the body pain associated to pegylated-interferon
(Brietzke et al., 2016) and TMS (Dall’Agnol et al., 2014). Another
system involved in the pain processing and perhaps in the effect
of treatment is the monoaminergic system, in which the COMT
enzyme plays a critical role in the degradation of catecholamines,
such as dopamine, where it transfers a methyl group of
S-adenosylmethionine to the 3-hydroxy group of catechol
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FIGURE 3 | Mechanisms engaged in the formation and maintenance of OIH. OIH, Hyperalgesia induced by opioids; BDNF, brain derived neurotrophic factor; Cx3Cl1,
chemokine Cx3Cl1; EAAC1, glutamate transporter EAAC1; GABAR, gamma aminobutyric acid receptor; GRK, G protein coupled receptor kinase; IL1β, interleukin
beta; IP3, inositol triphosphate; KCC2, K+/Cl cotransporter 2; LTP, long-term potentiation; MOR, mu-opioid receptor; mTOR, mammalian target of rapamycin; NO,
nitric oxide; NOS, nitric oxide synthase; NK1, neurokinin 1 receptor; NMDAR, N-methyl-D-aspartic acid receptor; PKC, protein kinase C; SP, substance P; TNFα,
tumor necrosis factor alpha; TrkB, tyrosine kinase B; TRPV1, transient receptor potential vanilloid 1; Ca2+, calcium; Cl−, chlorine; +, excitatory; –, inhibitory. (1)
Morphine activates the neuronal MOR and generates an intracellular process that culminates in the OIH; (2) Signaling mTOR is activated by morphine engaged in
neuroexcitation that lead to OIH; (3) The synaptic concentration of glutamate is elevated when the glutamate transporter EEAC1 are blocked by morphine. (4)
Glutamate coupling in your NMDA receptors activates the calcium influx inducing the LTP that lead an OIH. (5) The BDNF receptor TrkB reduces the action of the
cotransporter KCC2 evolved in ions chlorine homeostasis that modifies the inhibitory function of GABA for an excitatory function that which promote OIH. (6) Morphine
also activates the glial cells and neurons that generate pro-inflammatory cytokines (IL1β and TNFα) that induce LTP and lead to OIH.
(Axelrod and Tomchick, 1958). A functional polymorphism at
position 108/158 of COMT causes a valine amino acid exchange
for methionine (Val 108/158 Met) affects the thermal stability
of the enzyme as well as its activity. The Met allele results in a
more thermolabile and less active COMT phenotype (Lachman,
1996; Chen et al., 2004). The influence of serotonergic 5-HT1A
receptor promoter region polymorphism predicted the outcome
of the rTMS effect on depressive symptoms (Malaguti et al.,
2011). When tDCS was applied to the DLPFC it produced a more
significant reduction of auditory hallucinations in homozygous
for Val allele of the COMT polymorphism compared to carriers
of Met allele in schizophrenia (Shivakumar et al., 2015). In
healthy subjects, two reports demonstrated a specific interaction
of COMT polymorphism with both anodic and cathodic tDCS
during executive functioning using a Go/No-Go task (Plewnia
et al., 2013; Nieratschker et al., 2015). This task address different
aspects of executive functioning: sustained attention, inhibition
of response, and set change abilities (Langenecker et al., 2007).
In both experiments, the anodal tDCS (1mA) was applied
together with a cognitive task over the DLPFC. In the first
study, the effect of anodal tDCS was observed according to
Val158Met polymorphism of the COMT. Specifically, it was
found impaired by the set-displacement abilities, which in
homozygous for Met allele indicates a deterioration of cognitive
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FIGURE 4 | Areas of the brain that induction the descending pain inhibitory system composed by PAG-RVM-spinal cord pathway. TH, Thalamus; HT, hypothalamus;
AMY, amygdala; NCF, nucleus cuneiforms; PAG, periaqueductal gray matter; DLPT, dorsolateral pontine tegmentum; RVM, rostral ventromedial medulla. (1) Cortical
regions as cingulate and insula cortex as also the subcortical regions how the thalamus, hypothalamus, and amygdala project signals for the PAG, gray substance
located in the midbrain, that receives stimulus and send inhibitory impulses across the medial and lateral tracts of the CNS. (2) Medial tract: inhibitory and facilitatory
influence of the neurotransmitter serotonin in the pain activeness. (3) Lateral tract: dominant activity of neurotransmitter noradrenaline. (4) Fired inhibitory stimulus go
down throughout dorsal horn of the spinal cord segment. The painful stimuli are sent to the second order neurons. Endorphins, noradrenaline, and serotonin,
inhibitory neurotransmitters, are released activation of the inhibitory interneurons.
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flexibility but not in carriers of Val allele. In short, COMT
Val158Met polymorphism shown to shape the tDCS effects on
executive functions. However, the number of studies examining
this interaction is still small. Future studies are needed to
give extent data of the impact of genetic polymorphisms on
the variability of tDCS effects and to elucidate if they have
an essential effect that would help to define individualized
protocols in a translational research model. Besides, is necessary
to investigate if the therapeutic effect of tDCS may interfere on
the central mechanisms of pain and, if it could be an alternative
or complementary therapy to standard treatment options (e.g.,
opioids, antidepressants, anticonvulsants).
Dysfunction of Descending Pain Inhibitory
System
As mentioned above, the disruption in the balance between
excitatory and inhibitory neurobiological systems in opioids
tolerance and OIH can be linked to the dysfunction in the
DPIS. Although the somatotopic organization of DPIS influence
is quite diffuse, the pain inhibitory (DPI) pathways originate in
or relay through many brainstem nuclei namely the midbrain
periaqueductal gray (PAG) and the rostral ventromedial medulla
(RVM). The PAG-RVM system converges from other pain
modulatory areas thalamic, hypothalamic, and telencephalic
(cortical and subcortical) structures suppress pain through
descending projections to the spinal dorsal horn (Pertovaara
and Almeida, 2006). The descending circuitries involved in pain
inhibition have provided feedback control of nociceptive signals
at the spinal cord level (Pertovaara and Almeida, 2006). The
PAG neurons project to the raphe neurons, where do DPIS
effect is mediated by monoamines, peptides, and amino acids,
and by several different types of neurophysiological mechanisms
acting on central terminals of primary afferent nociceptive nerve
fibers, spinal interneurons, and spinal projection neurons. The
chronic painmay result in disorders of neurotransmitter systems,
which potentially lead to a decrease of DPIS function or an
increase of descending facilitation. The role of DPIS may be
enhanced by some centrally acting drugs (e.g., drugs acting
on the monoaminergic system, such as antidepressants with
dual or tricycle effect) (Pertovaara and Almeida, 2006).The
DPIS can be modulated either in a “top-down” manner, using
approaches to stimulate brain areas involved in descending
inhibitory controls [e.g., behavioral therapy, tDCS, transcranial
magnetic stimulation (TMS), etc.], or in a “bottom up”
activation with peripheral nerve stimulation (e.g., acupuncture,
electroacupuncture, etc.). Hence a better comprehension of
the relationship between the dysfunction in the DPIS induced
by opioids may contribute to finding factors involved in
the variability in pain sensitivity. Thereby, research can give
support for clinicians to understand factors that perpetuate
opioid use and barriers to detoxification (Volkow and McLellan,
2016). Aligned with this perspective the tDCS and other
neuromodulatory approaches can help in the management of
pain with lower risk of producing addiction, while it could reduce
the suffering when starting opioids dose reduction protocols
(Rieb et al., 2016).
The top-down pathways involved in the opioid-mediated
antinociception includes the modulatory effect mediated by
opioid receptors found in brain structures such as the anterior
cingulate cortex (ACC), midcingulate cortex (MCC), insula, PFC,
basal ganglia, amygdala, hypothalamus, DLPT, PAG, RVM, and
spinal cord. The role of the opioid system in inhibition of
fear acquisition was blocked by the MOR antagonist naloxone
in healthy subjects, as well as changes activation profile in
the amygdala (Eippert et al., 2009). In the same way, pain
expectations contribute to the placebo effect opioid-mediated
(Benedetti, 2005; Eippert et al., 2009). For instance, the naloxone
reduces the placebo effects in several cortical and subcortical
areas connected to the descending pain modulatory system
(e.g., rACC, PAG, RVM, and hypothalamus). The top-down
pathways involved in the opioid-mediated antinociception such
as PFC and ACC interact to limbic areas (e.g., amygdala and
insula) that provide relief of pain aversiveness (Navratilova et al.,
2015) and with the ventral striatum, that plays a central role
in rewarding behavior. Remarkably, all cortical inputs converge
to the PAG-RVM-spinal cord, which facilitates or inhibits
nociception (Fields, 2004; Jones and Brown, 2018) (Figure 4).
Transcranial Direct Current Stimulation:
Technical Factors and Neurobiological
Mechanism
The effect of non-invasive transcranial neuromodulation by
tDCS can be influenced by factors such as the regions where
the tDCS is applied (e.g., M1, DLPFC). This technique applies a
low and continuous electric current (oftenly from 0.5 to 2mA)
transmitted directly far to the electrodes (20–35 cm2) on the
scalp to a target area. In healthy subjects anodal tDCS, 0.5–
2.0mA resulted in similar facilitatory effects relative to sham
while for cathodal tDCS, only 1.0mA resulted in sustained
excitability diminution (Jamil et al., 2017). The current runs
through the scalp and reaches superficial cortical levels, acting
in the membrane polarity producing neuronal modulation in
these cortical regions. While anodal tDCS induces depolarization
and increases excitability, and cathodal decreases the excitability
in the neuronal membrane (Nitsche and Paulus, 2000; Priori,
2003; Lang et al., 2005; Nitsche et al., 2008). Anodal tDCS
induces depolarization the neuronal membrane and enhances
M1 excitability influencing the sensory-discriminative networks
evolved in pain sensitivity processing. Anodal stimulation over
DLPFC, on the other hand, has revealed beneficial effects on
mood regulation, cognitive functions (e.g., decision making) and
on mechanisms underlying adaptive and maladaptive emotional
functioning (Dixon et al., 2017).
Studies using in vivo magnetic resonance spectroscopy
(MRS) found that anodal tDCS reduces local cortical GABA
concentration in the motor cortex (Stagg et al., 2009; Kim
et al., 2014), it also increases local levels of glutamate and
glutamine (Glx) in the intraparietal and prefrontal cortex
measured together as combined Glx, and N-acetyl aspartate
(NAA) (Clark et al., 2011; Hone-Blanchet et al., 2016).
While studies that have investigated the effect of tDCS have
found cathodal tDCS conduct to a significant decrease in
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glutamate concentration compared to s-tDCS (Witney, 2018).
The tDCS effect on corticospinal excitability was blocked by
the NMDA-receptor antagonist dextromethorphan (Liebetanz
et al., 2002). This is compatible with activity-dependent synaptic
neuroplasticity, such as long-term potentiation (LTP) and long-
term depression (LTD). This experimental data give support
to comprehend the link between the cumulative effect induced
by repetitive sessions with the mechanisms of long-term
potentiation (LTP), or with increases in the facilitation process
or long-term depression (LTD). These neuroplastic mechanisms
involve the effect of central neurobiological systems related
to the excitability and inhibition, namely, glutamatergic and
GABAergic systems, respectively. Anodal stimulation induces
LTP provoked by neurotransmitters that facilitate the overture
of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid) channels and indirectly NMDA (N-methyl-D-aspartate)
receptor. The opposite occurs with a cathodic stimulation. These
effects are regulated by intracellular cyclic AMP and calcium
levels (Kronberg et al., 2019). Another mechanism involved in
pain relief through anodic stimulation is its capacity for restoring
the endogenous inhibitory system. Also, it has been showed that
tDCS could reach deeper structures such as red nucleus (RN)
and medial longitudinal fasciculus (MLF). tDCS can regulate cell
migration (McCaig et al., 2005; Zhao, 2009), cell orientation,
differentiation, andmetabolism. The changes in the direction and
speed of cell migration and neurite growth could be explained,
at least in part, by localized shifts of intracellular Ca2+ (Palmer
et al., 2000; Mycielska and Djamgoz, 2004). Thus, it facilitates
the opening of voltage-dependent ionic channels and NMDAR
activation (by removal of the blocking Mg2+ ions) (Pelletier and
Cicchetti, 2014). The intracellular signaling pathways triggered
by a substantial increase in postsynaptic calcium include
activation of protein kinase C, calcium/calmodulin-dependent
protein kinase II and tyrosine kinases. These molecular events
result in phosphorylation of AMPA receptors in the postsynaptic
membrane. Thereby, LTP is primarily expressed as an increase
in AMPA receptor-mediated (Nitsche et al., 2012b). When tDCS
stimulation is applied this induced LTP response, in an N-
Methyl-D-Aspartate Receptor (NMDA)-dependent fashion. The
LTP response is diminished in both sham and stimulated samples
when NMDAR antagonists are applied (Rohan et al., 2015) and
it is a fast-acting protein that allows for an influx of calcium
AMPA receptors, which is ionotropic glutamate receptors that are
permeable to cations, namely sodium and calcium ions (Chater
and Goda, 2014). The LTP response is diminished in both sham
and stimulated samples when NMDAR antagonists are applied
(Rohan et al., 2015).
Another factor that contributes to this neuromodulatory
action includes changes in the brain-derived neurotrophic factor
(BDNF) expression. An experimental study showed that ∼0.75
V/m anodal DCS increases the peak amplitude of the excitatory
postsynaptic potential. However, this effect was absent in slices
from BDNF knockout mice or when the TrkB receptor was
blocked (Fritsch et al., 2010). In individuals expressing the
BDNF Val66Met polymorphism, which affects the release of
BDNF, motor skill acquisition after a 5-day tDCS treatment
was significantly lower than in healthy volunteers (Pelletier
and Cicchetti, 2014). In short, its effect involves several
neurotransmitters, such as dopamine, acetylcholine, serotonin,
GABA (Medeiros et al., 2012), and multiple mechanisms of
intracellular plasticity, which affect neurotransmitters, including
gene expression. The cascade of the neurobiological processes
involving the tDCS effect is presented in Figure 5.
Transcranial Direct Current Stimulation to Treat Pain
and Dysfunctional Neuroplasticity Induced by
Opioids
The tDCS is a neuromodulatory technique promised to treat
opioid use disorder (OUD) in comparison to pharmacotherapy
and behavioral intervention strategies (Barr et al., 2011; Wing
et al., 2013; Salling and Martinez, 2016). While pharmacological
treatments are showing their limits, new therapeutic options that
are more targeted to the dysfunctional neural circuits are being
explored, such as tDCS. Although at present, the data are yet
incipient to know the real effectiveness in drug-avoiding behavior
(Fregni et al., 2008; Brangioni et al., 2018). It has been used to
inhibit craving behavior or to control pain, hence is attractive to
treating and preventing opioid dependence, respectively. Given
the impact of the epidemic of opioid addiction, innovative ways
are needed to help those currently addicted.
Effects of tDCS Applied Over M1 and DLPFC in Pain
Processing
The record of stimulation for motor cortex as a scientific
experiment occurred in 1780 when Galvani demonstrated the
electric contraction of the frog muscle. However, the first
electrical stimulation of the human brain was performed in
1874, when the motor cortex of an individual was exposed
during debridement of a focus of osteomyelitis in one area
of the scalp. tDCS was reintroduced as a non-invasive brain
stimulating the intact human cortex in the last two decades
(Nitsche and Paulus, 2000). The excitability depends on the
polarity of tDCS, anodal placed over M1 and cathodal over
frontal pole increase the excitability of M1 and it decreases
when current flow is reversed (cathodal placed over M1; Lang
et al., 2004). It is estimated that around 45% of the total current
applied to the scalp produces effective modulation of regional
neuronal activity in the targeted cortex (Rush and Driscoll,
1967). These changes in excitability persist beyond the time of
stimulation. The tDCS effect remains stable if it is used for at
least 10min (Nitsche and Paulus, 2001; Nitsche et al., 2003).
The M1 is somatotopically arranged to receive inputs from three
main sources: (i) peripheral inputs via thalamic relay nuclei-
somatosensory cortex, premotor cortex and sensory association
areas from the cortex; (ii) basal ganglia; and (iii) cerebellum.
The motor processing is overlap with those areas associated
with pain neuromatrix. Anodal stimulation is associated with
direct stimulation of pyramidal and cathodal is associated with
an indirect stimulation of pyramidal neurons via interneurons.
The processing of pain by tDCS involves different mechanism.
Stimulation in M1 lead to decrease in the hyperactivity of
thalamic and brainstem nuclei to result of the inhibition of
these areas. Indeed, anodal tDCS of M1 induce corticothalamic
inhibition of ventral posterolateral nucleus (VPL) responsible
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FIGURE 5 | M1, Primary motor cortex; DLPFC, dorsolateral prefrontal cortex; S1, primary somatosensory cortex; S2, secondary somatosensory cortex; PFC,
prefrontal cortex; ACC, anterior cingulate cortex; PCC, posterior cingulate cortex; INS, Insula; TH–VPL, thalamus-ventral posterolateral nucleus; TH-MD,
thalamus-medial dorsal nucleus; HT, hypothalamus; AMY, Amygdala; PAG, periaqueductal gray matter;RVM, rostral ventromedial medulla; NMDAR,
N-methyl-D-aspartate receptor; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; Trk, Tropomyosin receptor kinase; Ca2+, calcium; K+,
potassium; Na+, sodium; Mg², magnesium; +, excitatory; -, inhibitory; L-LTP, late long-term potentiation. (1) The anodal tDCS increases the intracellular Ca2+ flow
that releases more neurotransmitters. (2) The positive regulation of neurotransmitters facilitates the openness of AMPA channels and indirectly of NMDA channels,
which characterizes the long-term potentiation (LTP). (3) Activation of tropomyosin receptor (Trk) indicates the role of brain-derived neurotrophic factor (BDNF) in the
anodal tDCS; its effect increases the production of the synaptic vesicles and the neurotransmitter release. (4) Increase of Ca2+ flow promotes the release of
neurotrophic factors for the synaptic cleft. (5) Post-synaptic Trk receptor induces the late LTP (L-LTP) and favors the openness of the NMDA channels, which
reinforces the L-LTP. (6) Both L-LTP and L-LTD are highly dependent on the modification of gene expression.
for discriminatory sensitivity and ventral posteromedial nucleus
(VPM) responsible for nociceptive sensation. DLPFC stimulation
decreases the activity of the midbrain-medial thalamic pathway
being involved with the modulations of the structures related
to the emotional perception of pain (Boggio et al., 2008). The
right M1 activated by tDCS produced changes in the caudal
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portion of the anterior cingulate cortex, superior temporal
sulcus, right parieto-occipital junction, and cerebellum. This
effect indicates the functional interaction between M1 and these
areas via corticocortical and cortical-subcortical connections
(Lang et al., 2005).
The PFC can be divided intomedial prefrontal cortex (mPFC),
orbitofrontal cortex, ventrolateral, dorsolateral (DLPFC), and
caudal. DLPFC neurostimulation may modulate sustained and
divided attention when the tasks require workload. While the
frontal and parietal areas modulate the perceptual awareness,
and the right prefrontal areas may mostly control the internal
focus. Anodal over the left DLPFC may reduce the perceived
degree of emotional valence for negative emotional pictures
(Peña-Gómez et al., 2011), and for images of anger expressions
(e.g., De Raedt et al., 2010). Moreover, the left DLPFC
may play a role in the upregulation of reactions to positive
emotional stimuli, since anodal stimulation over this region
improves the identification of positive emotional expressions
(Nitsche et al., 2012a). On the other hand, the right DLPFC
may be involved in the upregulation of adverse psychological
outcomes. Stimulation with TMS using high frequency (i.e.,
excitatory) over the right DLPFC resulted in impaired attention
disengagement from threat (angry faces; De Raedt et al., 2010).
A similar result has been documented by Leyman et al. (2009),
showing that high-frequency rTMS over the right DLPFC
can reduce the ability to inhibit the processing of negative
information (sad faces). Thus, stimulation of both the left
and right DLPFC might counteract maladaptive plasticity of
the cortical-meso-limbic network according to the purpose
of treatment.
These findings indicate an important role of the PFC in pain
processing. Interestingly, the activity of DLPFC has been shown
to correlate negatively with the perception of pain, suggesting
that the DLPFC may have a dampening effect on the activity of
the midbrain-medial thalamic pathway. Thus, the DLPFC may
be activated during painful states and may in turn ultimately
modulate structures involved in the emotional perception of pain
including the anterior cingulate cortex, insula, and amygdala
(Boggio et al., 2008). A recent review expands this description,
highlighting the complex connections of other regions of PFC
with PAG, thalamus, amygdala and basal nuclei (Ong et al.,
2019). Thus, tDCS of DLPFC may interfere with the emotional
processing of pain by actively exerting control on pain perception
by modulating these subcortical and cortical pathways. tDCS
over prefrontal regions may exert an increased cerebral activity,
as investigated in EEG technique (Maeoka et al., 2012) and
can reduce pain or reduce the use of opioids in chronic pain
conditions such as myofascial pain (Choi et al., 2014), multiple
sclerosis (Ayache et al., 2016), and pain after lumbar spinal
surgeries (Glaser et al., 2016).
tDCS bilateral right anodal/left cathodal did not change the
sustained attention effect of tDCS (Heinze et al., 2014). Anodal
tDCS on the right DLPFC in comparison with anodal stimulation
to the left DLPFC induced higher improvement to analytical
judgment and decision-making, while the logic index score
diminished after left anodal stimulation. TDCS applied to the
right DLPFC is known to affect executive functions (Del Missier
et al., 2010) that include impulsivity control and set shifting (see
Greenwood et al., 2018, for a review).
EVIDENCE OF TDCS IMPACT ON PAIN
Systematized Review of Evidences
In order to understand qualitative and quantitatively the evidence
of the effects of tDCS on pain in chronic pain conditions,
we implemented a literature review and a meta-analysis of the
findings reported for pain levels after tDCS application.
Methods
A search in PubMed, Embase, and Cochrane databases was
performed inMay, 2019, in Title, Abstract, and Keywords (except
for PubMed, where all fields were examined). The scope of this
review included clinical trials with tDCS as the main intervention
for patients with chronic pain conditions. Therefore, we used
the following search term (boolean operators were changed
appropriately according to each database): [(“chronic pain” OR
“neuropathic pain” OR “myofascial pain” OR “musculoskeletal
pain” OR “migraine” OR “pain syndrome”) AND (transcranial
OR NIBS OR “non-invasive brain stimulation”)].
We excluded articles if they met the following criteria: studies
written in other languages than English, Portuguese, or Spanish;
studies that do not reported pain as an outcome; <5 sessions of
tDCS treatment; studies using other types of stimulation than
direct current; reviews and case studies; cross-sectional studies;
conference abstracts; tDCS protocols accepted were application
in areas of the primarymotor cortex (M1), dorsolateral prefrontal
cortex (DLPFC), or occipital area, considering low, or high-
density tDCS (HD-tDCS). In addition, studies should have
Baseline and post-tDCS treatment data available (mean and
standard-deviation or CI). The systematized search is presented
in Figure 6.
Results: Qualitative and Quantitative Data
Supplementary Table 1 presents methodological characteristics
and main findings of the 24 studies reviewed. Efficacy was
considered based on the effect sizes for the difference in Visual
Analogue Scale (VAS) or Numeric Pain Scale (NPS) scores (0–10)
between active and sham for the first measure after the complete
treatment. Positive values favor active stimulation. Six studies
had two possible comparisons with sham, and were included as
two entrances in the quantitative analyses. As can be observed,
publications in this field reviewed here start from 2006, since
the evidence related to our interest subject stated in this period.
Total sample sizes vary from 10 to 135 patients (mean = 35.1;
SD= 24.9) and include several different chronic pain conditions.
Considering all comparisons, number of tDCS sessions ranged
from 5 to 20 (mean = 8.4; SD = 4.5) and included anodal and
cathodal active stimulations, only tDCS or a combination of
tDCS and other intervention (combined interventions). Device
current ranged from 1 to 2 (mean = 1.7; SD = 0.5) and
application time ranged from 15 to 30min (mean = 20.2; SD =
2.3), considering in 92% of applications it lasted 20min.
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FIGURE 6 | Flowchart of the systematized search.
Results: Meta-Analysis and Risk of Bias
Assessment
For the meta-analysis, we followed the Cochrane guidelines
(Higgins et al., 2011) and used Review Manager 5 (RevMan
5.3) software to build forest plots, considering three scenarios:
all studies (Figure 7), studies using anodal M1 stimulation
site (Figure 8), and studies using anodal DLPFC (Figure 9),
regardless of the cathode or return electrode position. Only one
study was dropped from this analysis because data of treatment’s
end was not presented and could not be calculated, totalizing
23 works analyzed. For all studies, due to data had considerable
heterogeneity (I²= 71%), a random effects model was applied. A
total of 498 patients received active stimulation and most of the
studies favor active tDCS by showing a significant reduction (P
< 0.001) of pain levels (indexed by VAS or NPS measures) when
compared to sham tDCS. The standardized mean difference was
−0.66 (CI 95% = −0.91, −0.41). This means a reduction of
27.26% in pain at the end of treatment for active tDCS compared
to sham (95% CI; 15.89, 32.90%).
To investigate M1 efficacy, 20 studies were included.
Heterogeneity was identified, therefor random effects were
applied. A moderate effect size for reduction of pain levels was
able to be seen (−0.68; CI 95% = −1.0, −0.35). Finally, to
understand the efficacy of anodal DLPFC montages, four studies
were identified. No heterogeneity was found, and then fixed
effects model was applied. A moderate effect size was observed
(−0.54; CI 95%−0.91,−0.16).
For the analysis of Risk of Bias in the selected studies
we examined different potential sources of bias: selection bias
(random generation sequence and allocation concealment),
blinding (subject and assessor), incomplete outcome data
(attrition bias), selective reporting (reporting bias), other bias
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FIGURE 7 | Forest plot of the effects of tDCS on pain levels for all studies reviewed (n = 23).
FIGURE 8 | Forest plot of the effects of anodal M1 tDCS on pain levels (n = 20).
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FIGURE 9 | Forest plot of the effects of anodal DLPFC tDCS on pain levels (n = 4).
and possible limitations in relation to sample size and follow-
up assessments. We considered the criteria from Cochrane
guidelines (Higgins et al., 2011), as studies were evaluated
according to (a) low risk; (b) high risk; or (c) unclear. Following
the criteria of Andrew Moore et al. (2010) for evidence in studies
in chronic pain, sample sizes for each group/condition were
considered: (a) high risk for n < 50; (b) unclear (some risk)
from 50 to 199; and (c) low risk for n > 200. Follow-up quality
was judged as (a) high risk for <2 weeks after treatment; (b)
unclear (some risk) from 3 to 7 weeks; and (c) low risk for 8 or
more weeks. This assessment was implemented by two authors
independently. In case of disagreement, a third judge decided the
best option. Figure 10 presents the risk of bias assessment.
Integrating the Findings
This systematized review was able to evidence a significant
effect of tDCS in reducing the pain perception associated with
chronic pain conditions compared to sham with an effect size of
moderate magnitude (SMD= 0.66). Considering the diversity of
clinical conditions and treatment protocols (including combined
interventions), it is possible to conclude that this effect may be
clinically meaningful. However, we need parsimony to generalize
these findings to different contexts of chronic pain. Among
several aspects related to the primary outcome measures of
studies, we stress as main limitations: heterogeneity and measure
the outcome based in a unidimensional measure related to
severity [(e.g., pain scores on Visual Analogue Scale (VAS) and
Numerical Pain Scale (NPS-0-10)]. Also, distinct pathologies
with a small number of patients restrict the generalizability of
the impact of treatment. Furthermore, another point to consider
is that in small studies usually, the sample has more probability
of being a super-selected sample. Most of the studies have as
a primary outcome the pain severity by a unidimensional on
measures, and they are deprived of measures of disability due
to pain. In the same way, lack exploratory investigation of the
influence of other comorbidities (e.g., psychiatric disorders) in
the impact of tDCS. Although these studies have some limitations
related to how the measures the clinical impact the tDCS effects,
they are supported by data of complementary methods such as
neuroimaging and neurophysiological measures. These results
are essential to comprehend how the tDCS effect can change these
processes; however, we need to realize that they are surrogate
outcomes and were not the interest issue of this systematized
review. Bellow, we discuss the studies in detail, mainly focusing
onM1 and DLPFC anodal stimulations, to build up a perspective
of evidence.
Strength of Evidence for Pain Levels
According to the criteria adopted here, some studies
present major methodological weaknesses, which prevents
a straightforward conclusion about its findings. Therefore,
tDCS for reduction of pain levels in migraine is debatable, due
to problems in randomization, concealment of intervention,
missing data and selective reporting (Antal et al., 2011;
Auvichayapat et al., 2012). Nevertheless, they found a moderate
decrease (−36.4 and −31.5%, respectively) in pain after active
tDCS. For FM, seven studies were included. AlthoughMendonca
et al. (2016) did not find a positive effect of tDCS in pain
reduction when combined with an aerobic exercise (no additive
effect), the other studies had a significant impact and were
considered with low risk of bias (Fregni et al., 2006; Valle
et al., 2010; Fagerlund et al., 2015; Khedr et al., 2017). To
et al. (2017) had problems with blinding of assessors), either
using M1 of DLPFC anodal tDCS stimulation site, indicating
stronger evidence in this population. Concerning neuropathic
pain, three studies (Soler et al., 2010; Kim Y.J. et al., 2013;
Bocci et al., 2019) found reductions in levels of pain. They used
different anodal stimulation sites (M1, DLPFC, and cervical for
cerebellar stimulation) for various neuropathic pain syndromes.
Problems in randomization (except for Bocci et al., 2019) and
selective bias were found. Therefore, the evidence of an effect has
its limitations.
On the other hand, Wrigley et al. (2013), Lewis et al.
(2018), O’Neill et al. (2018) did not find any positive effect
of tDCS for pain reduction. They did not present significant
bias problems (although O’Neill et al., 2018 had a different
amount of tDCS sessions for each person), which raises a
conclusion of a lack of effects for the neuropathic syndromes they
investigated, including spinal cord and upper limb neuropathic
pain. One should consider that neuropathic pain syndromes
can vary a lot in terms of etiology and neurophysiological
mechanisms (Ramirez et al., 2013) and this heterogeneity, which
was the case in the present review, could be associated to
these findings.
Other studies evaluated tDCS effects in different pain
conditions. The more substantial impact was found for
myofascial pain syndrome (Sakrajai et al., 2014). The difference
between reduction after sham tDCS and after active anodal
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FIGURE 10 | Assessment of risk of bias from the reviewed studies (n = 24).
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tDCS over M1 for 5 consecutive days was 26.8%. However,
the study had problems with concealment of allocation, and
it did not present a protocol registration identified in a base
of clinical trials. Also, a significant decrease on pain scores
was also found for trigeminal pain (Hagenacker et al., 2014),
visceral pain due to hepatocellular carcinoma (Ibrahim et al.,
2018) and complex regional pain syndrome (Lagueux et al.,
2018). There was no significant effect on chronic low back
pain (Luedtke et al., 2015), even though this study had been
considered with minimal risk of bias. It is essential to realize low
back pain is a complaint of several distinct pathological insults,
including trauma, infection, inflammation, and systemic disease
such as cancer, etc. This condition can be classified broadly into
four pain states: nociceptive, inflammatory, neuropathic, and
centralized/dysfunctional. Therefore, this heterogeneity might
explain the lack of results. Another study (Antal et al., 2010)
also found significant reductions for pain severity (35% of
change from baseline for the active tDCS group), although it has
included 12 patients with various pain syndromes, encompassing
fibromyalgia, chronic back pain, trigeminal neuralgia, face pain,
arthrosis, post-stroke pain, and polyneuropathy.
Bringing into account this scenario, it could be suggested that
anodal tDCS may be useful in pain reduction. However, further
studies should consider the mechanisms underlying clinical
conditions and the pain state to personalize the therapeutic
approaches. Concerning the type of protocol, recent proposals
discuss a spatial-mechanistic framework (Yavari et al., 2017)
that should be considered when mounting tDCS, reasserting
the importance of electrode size and positioning. Besides, as
the guidelines for quality of evidence has evolved, researchers
should pay attention to some limitations found here. To the
risk of bias, the major problem was related to small sample
sizes for each treatment arm. Only two studies in our review
reached amoderate sample size as recommended by the IMPACT
guideline for chronic pain studies; the others had small sample
sizes. Follow-up assessment and research protocol registration
were also of some concern and should be considered in
future investigations.
Effect According to Site of Stimulation (M1
or DLPFC)
There is a contemporary debate about the best site for anodal
stimulation for pain syndromes. The M1 region has been
classically used and, as described on section Introduction, it
is an important part of the pain neuromatrix, with efferent
connections to many subcortical regions. The 20 trials that used
this montage observed a SDM equal to −0.68 (CI 95% = −1.00,
−0.35), which represents a moderate effect of active compared to
sham tDCS. On the other hand, we analyzed separately anodal
DLPFC effects, which was investigated through four studies,
three of them in fibromyalgia patients, and yielded an effect of
−0.54 for active compared to sham in reducing pain levels (CI
95% = −0.91, −0.16). Fregni et al. (2006) was the only study
that not found a significant effect of DLPFC on pain, although the
impact on depression and cognitive performance were reported.
This scenario indicates, at the first place, that DLPFC has a
potential effect in pain levels, although through different neural
mechanisms, even though a small number of studies has been
implemented so far. Second, the effects of the DLPFC may be
more pronounced for other clinical and behavioral measures, as
To et al. (2017) for fatigue effects and Fregni et al. (2006) for
emotional-affective and cognitive measures.
Evidence for Other Clinical Outcomes
Although the discussion so far has focused on the level of
pain (or severity of pain), it is crucial to be aware that this
outcome counts only partially to the health condition and
quality of life for patients with chronic pain. According to
IMMPACT, it is essential to consider besides pain level, the
physical disability, emotional functioning, participants’ ratings
of satisfaction, symptoms and adverse events, and participants’
disposition (Edwards et al., 2016). Thereby, we also considered
in this review other clinical measures that were investigated.
As described in Supplementary Table 1, many studies also
investigated depression and anxiety symptoms, and other
psychiatric symptoms and functional capacity or how much
pain impact daily life activities. Some studies also included
psychophysical measures of pain, such as pain threshold and
tolerance. A few have examined patient and physician global
impression of the treatment. IMMPACT suggested outcomes are
not observed in many studies, probably due to specific objectives
of some of them, which includes neurological, physiological and
biological measures, as well as criteria specific to the condition
investigated, which would result in excessive parameters to
be analyzed. Nevertheless, this points out to effects of tDCS
in other dimensions of pain, which requires further review
and meta-analysis.
Considerations of tDCS Application for
OUDs and Opioid Use for Chronic Pain
Syndromes
Few studies investigated the application of tDCS to counter-
regulate the dysfunction in the DPIS induced by opioids. In
healthy subjects in an experimental model, we showed that
the tDCS applied over M1 blocked the dysfunction caused by
remifentanil on the inhibitory pathways or up-regulation of the
pain-facilitating pathways (Braulio et al., 2018). This effect of
tDCS was demonstrated to prevent both the disengagement of
the DPIS and the summation effect on pain scores during the
cold pressor test (Braulio et al., 2018). When focusing on opioid
dependence, a recent review (Gallucci et al., 2019) found only one
study that used tDCS. Wang et al. (2016) reported a reduction
of 36.7% in craving for heroin after watching a real video of
heroin use in individuals who were addicted in the past and were
in abstinence for at least 1.5 years. Perhaps more interestingly
was Gallucci et al. (2019) findings related to pain and analgesic
use in postoperative contexts, based on seven studies. Although
only one study in postoperative acute pain found reductions
in pain perception after the procedure hallux valgus surgery
(Ribeiro et al., 2017), there were significant reductions in patient-
controlled analgesia (PCA) method in six studies (Borckardt
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et al., 2011, 2013, 2017; Dubois et al., 2013; Glaser et al., 2016;
Khedr et al., 2017). This effect ranged from small (0.3) to
large (0.95). Even though these results have been indicated an
important reduction in opioid use for certain conditions, to the
best of our knowledge, it is unknown the effect of tDCS to reduce
the opioid in chronic pain treatment use and to improve chronic
refractory pain in patients with opioid use in high doses and
a long-term.
Use of opioids are mandatorily associated with the severity
of pain reported, considering it is the leading information in
medical routines for the clinician to administer opioid drugs.
Psychological factors are also linked to OUD and addictive
behaviors (Darnall, 2012). It has been reported a bidirectional
relation between depression and opioid in chronic pain women.
Anxiety disorders are associated with more substantial use
of opioids. On the other hand, people with higher pain
catastrophizing, a psychological construct related to magnified,
ruminative, and helplessness thoughts have been linked to
inadequate response to opioid treatment. Thus, these measures
need to be considered in studies which focus on the reduction
of opioid use. Not only in OUD cases these measures might be
relevant, but also for opioid analgesics use in non-cancer chronic
pain conditions. Richards et al. (2018) found patients with lower
back pain using opioids for more than 3 months had a worse
attention performance and few pain self-efficacy beliefs than
patients not taking opioids. Problematic use of opioids in chronic
pain condition can affect up to 81% of patients, and addiction
can range from 8 to 12% (Vowles et al., 2015), which signals
to a significant health problem. Besides, the FDA recommends
that the better evidence on the severe risks of misuse and
with long-term use of opioids, predictors of opioid addiction
such as a history of previous dependence, psychiatric diagnosis,
benzodiazepine dependence, etc. Although the use of tDCS to
reduce cravings scores in OUDs is yet an emergent research
question, its effect finds plausibility to affect brain regions, which
are triggers for activation of dopaminergic circuitry (Strafella
et al., 2001; Pogarell et al., 2006).
In the same way, it may change the synaptic plasticity
in the reward system (Pascoli et al., 2014). In addition, the
activation of the frontal cortical region leads to changes in
cortical areas connected with behavioral inhibition or decision
making (Fecteau et al., 2014; Ouellet et al., 2015) and may
stimulate the subcortical regions related to the motivation
(Botvinick and Braver, 2015). However, further brain imaging
studies are required to elucidate the underlying mechanisms
following tDCS treatment to addiction. Aligned with data,
studies found that acute anodal tDCS over left DLPFC increased
the ability to resist smoking (Falcone et al., 2016). The left
cathodal and right anodal tDCS over bilateral DLPFC in a
single tDCS session reduced the activation of cingulate cortex
in crack-cocaine users during a visual test to assess the cortical
activation when a drug-user was exposed to a condition that
could get asses to drug (Conti and Nakamura-Palacios, 2014),
and tobacco intake (Fecteau et al., 2014). Furthermore, the tDCS
over the bilateral frontal-parietal-temporal (FPT) area has been
found to reduce cue-induced craving in nicotine dependents
(Meng et al., 2014).
PERSPECTIVES FOR FUTURE STUDIES
CONSIDERING THE IMPACT OF tDCS ON
DPMS AS AN APPROACH TO TREAT
THE OHI
Future Direction
The scientific advance of neuroscience has witnessed a huge leap
forward the comprehension of the mechanistic underpinnings
of pain. Also, the number of treatment targets has grown
substantially. However, despite these advances, at present,
in the clinical practice, we have not yet been able to apply
an evidence-based approach to chronic pain treatment that
reflects mechanistic understanding, and the clinical management
remains an empirical and often unsatisfactory journey for
patients. In this review, we propose an approach of usage of
transcranial neuromodulatory tools, specifically tDCS, for the
management of pain symptoms in chronic refractory pain
associated with OUD. We discussed the molecular mechanisms
and methods of assessment and management still fall well
short, as well as the opioid effects on pain pathways and how
they theoretically can disrupt the function of descending pain
inhibitory system. Our review struggles to show that common
difficulties when it comes to the treatment of pain condition in
OUD in clinical practice is related to the incipient understanding
pathophysiological pain mechanisms and how we could drive
a rational treatment choice. The current pain classification
is based mainly on descriptors, signs, and areas of the body
where pain symptoms are topically referred to, combined
with information regarding anatomical pathology (e.g., MRI
evidence of spinal stenosis). Rarely it is done in a perspective that
integrates a biopsychosocial framework. Nevertheless, substantial
improvements in chronic pain management could be possible
if a more strategic and coordinated approach could identify
specific mechanism, aligned with a biopsychosocial perspective
in accordance with the ACTTION-American Pain Society Pain
Taxonomy (AAPT), which include the following dimensions:
(1) core diagnostic criteria (e.g., symptoms, signs, diagnosis
tests, chronic pain condition, etc.); (2) standard features (e.g.,
location, temporal qualities, descriptors, fatigue, numbness,
etc.); (3) medical comorbidities (e.g., major depression); (4)
neurobiological, psychosocial, and functional consequences; and
(5) putative neurobiological and psychological mechanisms,
risk factors, and protective factors (central sensitization,
dysfunction of DPIS, somatosensory amplification) (Fillingim
et al., 2014). We integrate the consequence of chronic pain
treatments based on opioids, following recommendations of
guideline for opioid therapy in chronic non-cancer pain, which
recommended optimization of non-opioid pharmacotherapy
(anticonvulsants, antidepressants) and non-pharmacologic
therapy (electroacupuncture, physical activity, TMS, tDCS,
cognitive behavioral therapy, mindfulness, etc.), rather than a
trial of opioids (Busse et al., 2017). Their modest effect on pain
reduction supports the rationale to consider alternative theories
to opioids in non-cancer pain, and on functional improvement
in comparisons with no add-opioid to therapy (Busse et al.,
2017). Among several reasons that justify the short-term efficacy
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of opioids on long-term treatment, it is that the criteria used
to define the therapy have generally failed to account the
pathophysiology of pain, which focus in peripheral markers
of anatomic pathology and/or disease severity. In perspective,
this integrative view aims to consider the therapeutic effects by
impacting specific mechanisms, such as neurobiological and/or
psychosocial. That is, the diagnostic criteria for specific chronic
pain disorders should be determined based on mechanistic
and diagnostic evidence, rather than historical precedent or
theoretically expectancies. Aligned with this perspective, even
in the use of transcranial neuromodulatory approaches such as
tDCS, we could consider dimension to the neurobiological and
psychosocial factors that contribute to raise and to maintain
the chronic pain conditions. Considering the extensive review
here, it is plausible to conclude that the target (or a prioritized
target) of treatment needs to be defined before tDCS sessions
are applied. For instance if therapy focus on the impact of pain
severity on disability due to pain the major evidence points out to
apply anodal tDCS over M1. If the major concern are emotional
aspects related to pain, anodal tDCS over the left DLPFC
would be the indicated montage. If the purpose is to reduce
craving and addictive behaviors, the diencephalic montage where
anodal tDCS is applied to right DLPFC may be the first option.
Specifically, a stimulus in DLPFC can affect response inhibition,
and this area is involved in craving behavior, which includes
substance use disorder and behavioral addiction, modulating
cortical excitability. The methodology more often used for this is
right prefrontal anode and left the prefrontal cathode and from 1
to 2mA for 20min (Sauvaget et al., 2015). Also, the M1 is likely
more effective to improve the dysfunction of descending pain
modulatory systems. In short, tDCS could effectively improve
the disinhibited state of cortical neural circuits, resulting in better
control of both pain and pain-related emotions. Importantly, sex,
age, premorbid psychosocial functioning, duration of pain, its
local or widespread pain, medicines, etc. are factors that should
be considered in the therapeutic plan. Accordingly, we propose
that further studies follow a framework for pain management,
which would define the pain state, pain mechanism, and
molecular target. Such an approach could help as the foundation
for a new era of precision for pain therapy. They should
identify the pain state, considering that more than one can
be present (e.g., neuropathic, nociceptive, inflammatory, and
dysfunctional), to in the diagnosis the general pain mechanism
(nociceptive transmission, peripheral sensitization, ectopic
activity, central sensitization, and central disinhibition) and
molecular targets (e.g., BDNF Val66Met, MAO, and COMT
Val158Met genotypes, etc.).
According to a tool that we developed, in the validation
study, the method is safe with effects like observed in studies
that the stimulation was administered in medical centers.
According to a tDCS device developed in our research group,
the home-use method was found to be safe with effects like
observed in studies that the stimulation was administered in
medical centers. This device of tDCS that patients can apply
themselves allows programming the parameters of the stimulus
according to predefined by the clinician with a lock system
to avoid changes by other individuals. Besides, it will enable
monitoring the adherence to treatment by recording the time
of use, impedance, and current flow. The device can offer the
possibility to be to self-administration at home. Additionally, it
provides an option to be prepared with the type of stimulation
by a researcher not involved in the patients’ assessment to
allow an improvement in the quality of blinding. In short,
we present evidence for use in future research, including
psychosocial-social characteristics, sleep patterns, response to
test to pain (pain threshold, summation test, etc.), endogenous
pain-modulatory processes, and a possible response for the
pharmacologic challenge.
Limitations
The main limitation in this review is the number of articles
and the critical heterogeneity among them precluding drawing
more firm conclusions regarding the use of tDCS to prevent
and treat opioid dependence in chronic pain. However, this
is an important emerging research area that can have a
significant impact on public health, given the opioid epidemic
and given the lack of cost-effective alternatives. However, several
aspects emerge, mainly by the risk of bias analysis, small
sample size, heterogeneity, which reduces the strength of the
recommendation grade. The small patient series indeed hamper
the quality of evidence investigated, in the same way, are the
lack of adequate and accurate blinding. It is necessary more
data to have a more clear idea about the ability to maintain the
therapeutic effects over time since there is limited data related
to long-lasting stimulation protocols as well as lack of data
regarding the influence of age and time of day that the stimulation
was applied.
Although the research with tDCS for the treatment of OUD
shows useful perspectives, these results are preliminary and
further research is needed. Further studies are required to
understand differences in efficacy according to the targeted brain
region. Furthermore, another gap that persists to be investigated
is the polysubstance use disorders and co-occurring psychiatric
disorders. Finally, we need studies to understand the potential
benefits of concurrent therapies (pharmacological, behavioral)
or the use of brain stimulation to prevent a participant’s
chances of becoming abstinent. Also, another gaps in the
literature are worth noting, including the lack of optimal brain
stimulation parameters in OUDs and data related to the effect
the tDCS combination studies with approved pharmacological,
and behavioral treatments.
CONCLUSION
In comparison with sham stimulation, tDCS applied over M1
demonstrated a superior effect in reducing pain severity in
non-cancer chronic pain conditions. Although the impact of
tDCS over the left DLPFC indicates beneficial effects, the
number of studies is smaller and more investigations are
needed to allow definitive conclusions. However, in most of
the studies, the number of patients is <50, and follow-up
evaluations are performed <3 months. In overall, these results
give perspectives that top-down neuromodulatory effects of tDCS
are a promising approach to improve management in refractory
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non-cancer chronic pain and to enhance dysfunctional neuronal
circuitries involved in the DPIS and other pain dimensions,
such as emotional and cognitive. However, further studies are
needed to determine individualized protocols according to a
biopsychosocial perspective.
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